| 6.245 0.025 (0.4%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.37 | 1-year : | 9.78 |
| Resists | First : | 7.17 | Second : | 8.37 |
| Pivot price | 6.34 |
|||
| Supports | First : | 5.9 | Second : | 5.11 |
| MAs | MA(5) : | 6.44 |
MA(20) : | 6.3  |
| MA(100) : | 5.52 |
MA(250) : | 5.56 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 33.5 |
D(3) : | 42.2 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 7.32 | Low : | 3.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABEO ] has closed above bottom band by 36.9%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.31 - 6.35 | 6.35 - 6.39 |
| Low: | 6.02 - 6.07 | 6.07 - 6.11 |
| Close: | 6.18 - 6.24 | 6.24 - 6.31 |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Thu, 05 Jun 2025
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Mon, 02 Jun 2025
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 02 Jun 2025
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Fri, 30 May 2025
Abeona Therapeutics Leadership to Share Latest Company Updates at Major Healthcare Conference - Stock Titan
Fri, 16 May 2025
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Positive Developments | ABEO Stock News - GuruFocus
Thu, 15 May 2025
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 63.1 (%) |
| Shares Short | 5,890 (K) |
| Shares Short P.Month | 2,760 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50 % |
| Return on Equity (ttm) | -271.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.68 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -9.92 |
| PEG Ratio | 0 |
| Price to Book value | 7.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.34 |
| Dividend | 3 |
| Forward Dividend | 0 |
| Dividend Yield | 48% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|